The longevity dividend: Why governments and markets must catch up

How much' often matters less than 'how fast' .Financial systems might comfortably accommodate a decade increase in life expectancy if it emerges gradually over half a century, but could they accommodate the same increase within 5 years?Economies are built to absorb gradual change and are much less comfortable with discontinuities.Human longevity may be approaching that kind of discontinuity.The latest scientific advances point to the emergence of what we have termed 'system-level' therapeutics (Kern, Jenkins et al., 2025;Kern et al., 2024), capable of bringing about rapid, non-linear changes in both healthspan and lifespan trajectories, challenging the incremental paradigms that underpin current economic and demographic forecasting models.If they do, governments, healthcare systems, insurers and pension funds will have to respond to a break with history, not a continuation of it.In this paper, we introduce a new conceptual framework that classifies therapeutic interventions according to their biological scope: symptom-management, single-disease causal therapeutics and system-level therapeutics.The first two categories represent the traditional paradigm of medicine, in which therapies are directed at managing symptoms or treating individual diseases.In contrast, the third captures an emerging generation of system-level interventions that target shared biological mechanisms across multiple age-related diseases simultaneously (Kern, Jenkins et al., 2025).We outline the expected effects of each category on healthspan, lifespan and downstream economic outcomes.The framework provides a structured way to compare both conventional and the latest emerging therapeutic strategies and to trace how their differing biological impacts propagate through healthcare systems, labour markets, public finances, insurance, and economic productivity.